Author

R. Meshkani

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Co-administration of empagliflozin and curcumin attenuates the development of MASLD by modulating lipid metabolism and adipose tissue browning in HFD-fed C57BL/6J mice.

The increasing global incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) highlights the need for effective treatment strategies. This study investigated the combined effects of empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and curcumin (Cur), a natural polyphenol,...

Masoume Aliabadi, A. Soleimani, G. Taheripak et al. · Life Science · 0 citations

Review Open access Jan 2026

Dual Roles of Natural Products in Regulating Ferroptosis in Acute and Chronic Liver Diseases: A Review

Liver diseases, both acute and chronic, are a major global health burden with limited therapeutic options. Ferroptosis, an iron‐dependent form of regulated cell death driven by lipid peroxidation, has emerged as a key contributor to liver pathology and a potential therapeutic target. This review examines how plant‐deri...

Farshad Niazpour, R. Meshkani · Oxidative Medicine and Cellu... · 0 citations

Oct 2026

Combination of Empagliflozin and Resveratrol Mitigates Hepatic Steatosis via Attenuation of Inflammation and Promotion of Adipose Tissue Browning in High‐Fat Diet‐Fed C57BL/6J Mice

The combined effects of empagliflozin and resveratrol treatment on obesity‐associated MASLD in a high‐fat diet (HFD)‐fed mouse model reduced body weight gain and improved glucose tolerance more effectively than monotherapies.

A. Soleimani, Masoume Aliabadi, Jamal Amri et al. · The FASEB Journal · 0 citations